# Evidence Summary — Vascular Behçet, Adalimumab, Colchicin, Eliquis

_Last updated: 2026-06-21T20:38:06+02:00_

## Clinical question
For Sir: vascular Behçet phenotype with thromboses/thrombophlebitis context; evaluate relevance of **Adalimumab/Humira**, and whether `Colchicin` and `Eliquis/Apixaban` could later be reduced.

## Current synthesis
### 1. Adalimumab
Adalimumab is a plausible escalation/biologic option for venous vascular Behçet, especially if disease is active, recurrent or insufficiently controlled. Best currently saved direct evidence: Emmi et al. 2018 retrospective 70-patient cohort showing faster/more frequent clinical + imaging improvement of venous thrombosis versus DMARDs and steroid-sparing effect.

### 2. Immunosuppression core principle
Behçet-associated thrombosis is commonly framed as **inflammation-induced thrombosis**. Therefore disease control via immunosuppression/biologics is not optional decoration; it is the central mechanism-targeted treatment.

### 3. Anticoagulation additionally to IS
Older guideline framing: immunosuppression primary; anticoagulation controversial. EULAR 2018: anticoagulants may be added if bleeding risk is low and pulmonary artery aneurysms are ruled out.

Newer 2024/2025 data nuance this:
- Erol et al. 2024: retrospective data suggested IS + AC had lower recurrence than IS alone.
- Omar et al. 2025 systematic review: AC may help in selected VBD contexts, but benefit not uniform.
- Chuklin et al. 2025 meta-analysis: combined IS + AC had lower pooled thrombosis relapse than IS alone or AC alone, though evidence mostly retrospective.

### 4. Eliquis/Apixaban reduction
Do **not** treat Adalimumab start as automatic permission to reduce Eliquis. Reduction should be a later, objective, clinician-led decision. Required discussion points:
- Current thrombosis/SVT activity?
- Baseline and follow-up venous imaging?
- Pulmonary/arterial aneurysm status?
- CRP/BSG trend?
- Any thrombophilia/risk factors?
- Exact relapse prevention strategy if Eliquis is reduced?

### 5. Colchicin reduction
Colchicin is more relevant to mucocutaneous, joint and some superficial inflammatory/vascular manifestations. It may be more taperable than Eliquis after stable biologic response, but not as first reflex. Prefer: start/establish Adalimumab → prove stability over months → discuss taper.

## Practical Arztgespräch questions
1. Is my current vascular issue active inflammation or residual/post-thrombotic state?
2. Which imaging should be baseline before Adalimumab and before changing Eliquis?
3. Have pulmonary artery aneurysms or other arterial aneurysms been ruled out?
4. What is the explicit goal of Eliquis: acute therapy, secondary prophylaxis, bridge until IS works, or longer-term recurrence prevention?
5. Which objective criteria must be met before reducing Eliquis?
6. Is Adalimumab sufficient or should Infliximab be considered for my vascular phenotype?
7. What infection screening/vaccines before TNF inhibition?

## Saved sources
- `studies/2018_emmi_adalimumab_vs_dmards_venous_thrombosis.md`
- `studies/2023_kaban_adalimumab_leg_ulcers_behcet.md`
- `sources/eular_2018_vascular_behcet_anticoagulation.md`
- `studies/2024_erol_is_plus_anticoagulation_recurrent_thrombosis.md`
- `studies/2025_anticoagulation_systematic_reviews.md`